NasdaqGM - Nasdaq Real Time Price USD

Connect Biopharma Holdings Limited (CNTB)

0.6838

-0.0631

(-8.45%)

As of 3:08:23 PM EDT. Market Open.

Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / April 11, 2025 / RedChip Companies will air interviews with Bullfrog AI Holdings, Inc. (Nasdaq:BFRG) and Connect Biopharma Holdings Limited (Nasdaq:CNTB) and on the RedChip Small Stocks, Big Money™ show, a sponsored ...

ACCESS Newswire 11 days ago

CNTB
-8.45%
BFRG

BFRGW
Talkspace And 2 Other Promising Penny Stocks

As the U.S. stock market grapples with significant volatility, highlighted by recent sharp declines in major indices due to tariff tensions, investors are increasingly looking for opportunities that may offer resilience and potential growth. Penny stocks, a term often associated with smaller or newer companies, continue to hold relevance as they can present unique investment opportunities at lower price points. When these stocks are backed by strong financials and sound fundamentals, they may...

Simply Wall St. 15 days ago

CNTB
-8.45%
CSTE

TALK
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

– FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Expect to initiate both trials in Q2 2025 – SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or Connect Biopharma), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announce

GlobeNewswire 21 days ago

CNTB
-8.45%
Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

– Rademikibart demonstrated rapid onset of action with significant improvements in lung function observed at one week and maintained through 24 weeks – – In patients with eosinophilic-driven asthma (≥300 eosinophils/µL) receiving rademikibart for 24 weeks, the mean difference from placebo in forced expiratory volume was +420 mL, amongst the largest increases reported for a biologic – SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharm

GlobeNewswire 21 days ago

CNTB
-8.45%
Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

Strengthened leadership team with key appointments, including Barry Quart, Pharm.D. as CEO, and David Szekeres as President, bringing deep clinical, regulatory, operational and strategic expertise Unveiled rapid clinical development program for rademikibart initially targeting acute care in asthma and COPD; expect to initiate parallel Phase 2 trials in 2Q 2025 with data expected in 2H 2026 Strong balance sheet with cash runway into 2027 and through key clinical catalysts SAN DIEGO, March 31, 202

GlobeNewswire 22 days ago

CNTB
-8.45%
Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD), today announced that it received a letter dated March 24, 2025 from the Listings Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) indicating that, for the last 30 consecutive business days, the bid pri

GlobeNewswire 24 days ago

CNTB
-8.45%
Connect Biopharma to Present at Two Upcoming Investor Conferences

SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care in Asthma and Chronic Obstructive Pulmonary Disease (COPD), today announced that company management will participate in the following upcoming conferences: Leerink Partners Global Biopharma ConferenceFormat: Fireside ChatDate: Wednesday, March 12, 2025Time: 1:40 p.m. ETWebc

GlobeNewswire last month

CNTB
-8.45%
Connect Biopharma Holdings And Two Other Promising Penny Stocks To Watch

The U.S. stock market has experienced a mix of volatility and optimism recently, with inflation readings easing concerns about potential interest rate hikes. Amidst these fluctuations, penny stocks remain an intriguing segment for investors seeking growth opportunities at lower price points. Although the term 'penny stock' might seem outdated, these smaller or newer companies can still offer significant potential when supported by strong financials and solid fundamentals.

Simply Wall St. last month

CNTB
-8.45%
DLTH

MOGU
3 US Penny Stocks With Market Caps Under $400M To Consider

As the United States market experiences a late-year slump, with major indices like the Dow Jones and S&P 500 turning lower, investors are increasingly looking for opportunities outside of large-cap stocks. Penny stocks, despite their somewhat outdated name, remain an area of interest for those seeking smaller or newer companies that may offer unique value propositions. This article will explore three penny stocks that stand out due to their financial strength and potential for long-term...

Simply Wall St. 3 months ago

CNTB
-8.45%
OIS

XNET
US Penny Stocks To Monitor In November 2024

As of mid-November 2024, the U.S. stock market has experienced a downturn, with major indexes recording weekly losses due to challenges faced by big-tech companies and concerns over interest rate policies. For investors willing to explore beyond the well-known giants, penny stocks—often representing smaller or newer enterprises—can still offer intriguing prospects. Despite being considered a somewhat outdated term, these stocks remain relevant for those seeking growth opportunities in...

Simply Wall St. 5 months ago

LTRX

CNTB
-8.45%
ARDX
Attovia Therapeutics Appoints Chief Financial Officer

Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial OfficerFREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and operational experience and joins Attovia after serving as Chief Financial Officer at Connect Biopharma (NASDAQ: CNTB), a global clinical-stage biopharmaceutical company focused on T cell-driven therapeutics for inflammatory d

GlobeNewswire 6 months ago

CNTB
-8.45%
Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024

SAN DIEGO, CA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a U.S.-headquartered global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases, today announced that Connect Biopharma’s management team will participate at the Cantor Fitzgerald Global Healthcare Conference 2024 taking place in New York, NY on September 17th – September 19th. Details o

GlobeNewswire 7 months ago

CNTB
-8.45%
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

Announced new U.S.-based leadership with the appointment of Barry Quart, Pharm.D. as Chief Executive Officer (CEO) and David Szekeres as PresidentConnect’s new management is currently evaluating the future clinical development strategy for rademikibartAs part of Connect’s transformation into a U.S.-centric company, the Company will be significantly reducing its presence in ChinaCash and cash equivalents of $110.2 million expected to support planned operations into at least the first half of 2027

GlobeNewswire 7 months ago

CNTB
-8.45%
Connect Biopharma Holdings (NASDAQ:CNTB) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. 7 months ago

CNTB
-8.45%
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that Barry Quart, Chief Executive Officer, David Szekeres, President and Steven Chan, Chief Financial officer will b

GlobeNewswire 9 months ago

CNTB
-8.45%
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that the Board of Directors (Board), including all of the independent directors of the Board, granted to Barry Quart

GlobeNewswire 10 months ago

CNTB
-8.45%
Connect Biopharma Announces New Leadership and Chair of the Board of Directors

Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transitionExperienced life science executive David Szekeres appointed as PresidentKleanthis G. Xanthopoulos, Ph.D. appointed as Chair of the Board of Directors SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-

GlobeNewswire 10 months ago

CNTB
-8.45%
GRI
Connect Biopharma Holdings Limited's (NASDAQ:CNTB) top owners are private equity firms with 39% stake, while 22% is held by insiders

Key Insights Significant control over Connect Biopharma Holdings by private equity firms implies that the general...

Simply Wall St. 10 months ago

CNTB
-8.45%
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24Significant improvement in patient-reported asthma control occurred early and was sustained through Week 24End of Phase 2 (EoP2) meeting is scheduled with the U.S. Food and Drug Administration (FDA) for Q2 2024 SAN DIEGO, CA and TAICANG, China, May 22, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or t

GlobeNewswire 10 months ago

CNTB
-8.45%
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced data from its global Phase 2b trial of rademikibart in patients with moderate-to-severe asthma was accepted as a late-break

GlobeNewswire 11 months ago

CNTB
-8.45%

Performance Overview

Return	CNTB	MSCI WORLD (^990100-USD-STRD)
YTD	-46.16%	-6.22%
1-Year	-55.60%	+5.94%
3-Year	-76.50%	+20.62%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Connect Biopharma Holdings Limited (CNTB)

Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Talkspace And 2 Other Promising Penny Stocks

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Connect Biopharma to Present at Two Upcoming Investor Conferences

Connect Biopharma Holdings And Two Other Promising Penny Stocks To Watch

3 US Penny Stocks With Market Caps Under $400M To Consider

US Penny Stocks To Monitor In November 2024

Attovia Therapeutics Appoints Chief Financial Officer

Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

Connect Biopharma Holdings (NASDAQ:CNTB) Is In A Good Position To Deliver On Growth Plans

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

Connect Biopharma Holdings Limited's (NASDAQ:CNTB) top owners are private equity firms with 39% stake, while 22% is held by insiders

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

Performance Overview